Ahlstrom: Information regarding publication of FY 2025 financial results

Ahlstrom will publish its Financial Statements Release 2025 on Thursday, 26 February 2025 at ~09:00 EET with a combined live audiocast and teleconference at 15:00 EET hosted by CEO Helen Mets and CFO Niklas Beyes. The company notes 2024 net sales of EUR 3.0 billion and roughly 7,000 employees; the release and event (registration links provided) are standard investor-relations activity and may prompt investor attention but contain no operational or guidance detail in this notice. Contact for investor queries is listed (Tomi Lindell).

Analysis

Market structure: The February 26 FY2025 release is a short-term liquidity event for Ahlstrom and its specialty-material peers — expect a 24–72h window of 5–15% intraday moves depending on guidance vs consensus. Winners: filtration, life-science and protective-material niches if management signals durable pricing or capacity discipline; losers: commodity paper/pulp peers if Ahlstrom warns on packaging cyclicality. The report will recalibrate relative multiples across specialty vs commodity materials in Europe (re-rating range ±0.5–1.0x EV/EBITDA).

Risk assessment: Tail risks include a sudden margin squeeze from raw-material (pulp, polymers) cost spikes, an adverse FX/hedging disclosure (EUR exposure), or a guidance cut that forces covenant breaches; probability low-moderate but impact high (share drop 15%+, credit spread widening). Immediate horizon (days): volatility spike; short-term (weeks): guidance digestion and analyst revisions; long-term (quarters): execution on filtration/Life Sciences growth and net-debt trajectory. Hidden dependencies: order backlog health in medical filtration and timing of capex ramp for new lines could produce second-order margin effects.

Trade implications: Direct short-duration plays include a small long-Ahlstrom position into the print with defined downside protection and a relative-value pair vs UPM-Kymmene (UPM.HE) to isolate specialty vs commodity exposure. Options: if implied vol cheap (<30% on Helsinki options), buy a 30-day straddle/long-call spread sized 0.5–1% NAV; if expensive, use a collar. Rotate 1–3% allocation from commodity paper names into specialty materials/filtration stocks or XLB over 1–3 months.

Contrarian angles: Consensus will underweight the structural resilience of filtration/Life Sciences; if management reiterates secular demand (medical/air filtration), the stock can gap +8–12% on forward-margin upgrades. Conversely, if market fixates on packaging softness, overreaction of −12%+ could present a 6–12 month buying opportunity if net-debt/EBITDA stays <=2.5x and organic growth re-accelerates to +3%+. Monitor guidance vs three KPIs to detect mispricing.

Key Decisions for Investors

• Establish a 2–3% long position in Ahlstrom (Ahlstrom Oyj) ahead of the Feb 26 FY2025 release; size position to risk a 6% adverse move, and buy a 30-day protective put (or set a hard stop at −6%).
• Set conditional add: if company reports organic revenue growth > +3% YoY and adjusted EBIT margin expands >=100bps, increase exposure to 4–5% weight within 2 weeks post-release; if organic growth < 0% or net debt/EBITDA > 2.5x, reduce position by 50% immediately.
• Construct a relative-value pair: long Ahlstrom (2% NAV) vs short UPM-Kymmene (UPM.HE) (2% NAV) for 1–3 months to capture specialty over commodity exposure; unwind after confirmation of FY26 guidance or after 10% differential move.
• If options liquidity exists, buy a 30-day ATM straddle sized 0.5–1% NAV into the print if implied volatility < 30%; if IV > 35%, instead buy a 30-day call spread (buy ATM, sell +15% OTM) to cap premium.
• Rotate 1–3% of portfolio from commodity paper/pulp stocks into specialty materials/filtration (or XLB) over the next 4–12 weeks; target rebalancing if sector dispersion > 8% or Ahlstrom forward EBITDA multiple moves ±0.5x vs peers.